View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 2, 2020updated 12 Jul 2022 11:57am

AbbVie’s venetoclax misses Phase III endpoint in AML patients

AbbVie has reported that the Phase III VIALE-C clinical trial of venetoclax (Venclexta) plus low-dose cytarabine (LDAC) failed to reach the primary goal in patients with acute myeloid leukaemia (AML).

AbbVie has reported that the Phase III VIALE-C clinical trial of venetoclax (Venclexta) plus low-dose cytarabine (LDAC) failed to reach the primary goal in patients with acute myeloid leukaemia (AML).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Venetoclax specifically binds to and inhibits the B-cell lymphoma-2 (BCL-2) protein, which blocks some cancer cells from undergoing their natural death.

The randomised, double-blind, placebo-controlled Phase III trial compared the safety and efficacy of venetoclax combination to placebo plus LDAC, in a total of 210 treatment-naïve AML patients.

Primary efficacy endpoint of the study was overall survival (OS). The trial also assessed secondary endpoints such as remission rates, transfusion independence and event-free survival.

AbbVie’s drug combination did not show statistically significant improvement in OS, where the treatment led to a 25% decrease in the risk of death versus to LDAC with placebo.

The venetoclax arm demonstrated a median OS of 7.2 months compared to 4.1 months in the LDAC arm.

Data from a posthoc analysis after an additional six months of follow up revealed 8.4 months of increase in median OS with the venetoclax combination and 4.1 months with the placebo combination.

The safety profile of the combination is said to be consistent with the Phase I / II data, which supported the US Food and Drug Administration (FDA) approval of the combination in other indications.

AbbVie chief medical officer and development vice-president Neil Gallagher said: “We remain committed to AML patients and our research in AML and other blood cancers.

“The study results, while not statistically significant, are indicative of the clinical activity of venetoclax in combination with low-dose cytarabine.”

AbbVie is developing the drug in alliance with Roche. It is co-commercialised by AbbVie and Roche unit Genentech in the US and by AbbVie alone outside of the US.

AbbVie develops medicines that deliver transformational improvements in cancer treatment by uniquely combining knowledge in core areas of biology with cutting-edge technologies.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena